Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy.
Carla MinoiaVincenza de FazioGiovanni ScognamilloAnna ScattoneNicola MaggialettiCristina FerrariAttilio GuariniPublished in: Diagnostics (Basel, Switzerland) (2019)
Myeloid sarcoma (MS) represents a rare disease with an adverse clinical outcome for patients not candidate to acute myeloid leukemia (AML)-like chemotherapies. Here we present the case of an elderly patient affected by a bilateral breast localization of MS treated with the hypomethylating agent decitabine associated to radiotherapy. The association of the two treatment modalities has allowed an optimal and long-lasting disease control.
Keyphrases
- acute myeloid leukemia
- allogeneic hematopoietic stem cell transplantation
- newly diagnosed
- early stage
- mass spectrometry
- end stage renal disease
- multiple sclerosis
- ms ms
- chronic kidney disease
- ejection fraction
- radiation therapy
- locally advanced
- radiation induced
- bone marrow
- rectal cancer
- systemic lupus erythematosus
- acute lymphoblastic leukemia
- patient reported outcomes
- patient reported
- adverse drug
- drug induced